menu
    • menu
    PHARMACOMPASS
    PHARMACOMPASS

    Grow Your Pharma Business Digitally
    X
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Lupin Gets Tentative U.S. FDA Approval For Ivacaftor Oral Granules

    EXPRESSPHARMA

    Vertex Announces FDA Approval for Trikafta to Non-F508del Variants

    BUSINESSWIRE

    Vertex inks long-term access deal for CF meds in Englan

    FIERCE PHARMA

    Vertex Receives CHMP Positive Opinion for KALYDECO® for Cystic Fibrosis

    BUSINESSWIRE

    Vertex`s sales of Trikafta hit $8.9B thanks to label expansion

    FIERCE PHARMA

    Vertex meets own cystic fibrosis record with next-gen treatment

    FIERCE BIOTECH

    Vertex Announces EMA Validation for MAA Extension for KAFTRIO

    BUSINESSWIRE

    EC Approves KAFTRIO® in Combination With Ivacaftor

    BUSINESSWIRE

    NICE rejects cost effectiveness of Vertex`s cystic fibrosis meds

    FIERCE PHARMA

    Vertex Receives CHMP Positive Opinion for KAFTRIO

    BUSINESSWIRE

    European Commission Approves ORKAMBI for Cystic Fibrosis

    BUSINESSWIRE

    Vertex secures FDA clearance for infants’ cystic fibrosis therapy

    PHARMACEUTICAL TECHNOLOGY

    Vertex Announces U.S. FDA Approval for TRIKAFTA in Children With Cystic Fibrosis

    BUSINESSWIRE

    Vertex Announces U.S. FDA Approval for TRIKAFTA in Children With CF

    BUSINESSWIRE

    Vertex Announces Health Canada Market Authorization for ORKAMBI& in Children

    BIOSPACE

    In Cystic Fibrosis Failure, Eloxx Sees Silver Lining for Alport Syndrome

    BIOSPACE

    Vertex (VRTX) CF Drug Gets FDA Expanded Label for Toddlers Nasdaq

    NASDAQ

    Vertex Announces U.S. FDA Approval for ORKAMBI in Children

    BUSINESSWIRE

    FDA Confirms Paragraph IV Patent Litigation for Aprepitant, Azilsartan, Bupivacaine, Cladribine, Elrombopag, Fosnetupitant, Fostamatinib, Ivacaftor and Sodium Thiosulfate.

    FDA

    FDA confirms Paragraph IV Patent Litigation for Ivacaftor

    FDA

    Lupin gets US FDA nod for generic drug

    EXPRESS PHARMA

    Lupin`s Generic Ivacaftor Receives Approval in the US

    FDA

    Health Canada Grants Marketing Authorization for TRIKAFTA

    BUSINESSWIRE

    Vertex Announces Reimbursement Agreement in Australia for TRIKAFTA

    BUSINESSWIRE

    European Commission approves cystic fibrosis treatment for six to 11-year-olds

    PHARMATIMES

    EMA recommends approval of Kaftrio + ivacaftor in 6-11Y age of children with CF

    PHARMABIZ

    Health Canada accepts Priority Review of Vertex`s sNDA for KALYDECO in CF

    BIOSPACE

    Vertex Announces Letter of Intent With pan-Canadian Pharmaceutical Alliance

    BIOSPACE

    Health Canada approves Vertex Pharma’s Prkalydeco to treat infants with CF

    PHARMABIZ

    Vertex Announces Publication in The New England Journal of Medicine

    BUSINESSWIRE

    Vertex Announces National Reimbursement Agreement in France for KAFTRIO

    BUSINESSWIRE

    Health Canada Grants Marketing Authorization for TRIKAFTA

    BUSINESSWIRE

    Vertex Announces U.S. FDA Approval for TRIKAFTA

    BUSINESSWIRE

    Vertex Announces European Commission Approval for SYMKEVI®

    BUSINESSWIRE

    Vertex’s Kalydeco scores another label extension in EU

    PHARMATIMES

    Vertex Announces European Commission Approval for KALYDECO® (ivacaftor)

    BUSINESSWIRE

    Vertex Announces European Commission Approval for KALYDECO® (ivacaftor)

    PHARMIWEB

    FDA Approves Kalydeco for Infants as Young as 4 Months

    CFF

    Vertex gets FDA nod to Kalydeco for cystic fibrosis in 4 to 6-month infants

    SEEKING ALPHA

    FDA Approves KALYDECO® as 1st & Only CFTR Modulator to Treat Eligible Infants

    BUSINESSWIRE

    Vertex to Present New Data at Virtual Cystic Fibrosis Conferences

    BUSINESSWIRE

    Positive Ph3 Study TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor)

    BIOSPACE

    Vertex Announces Expansion of Reimbursement Agreement With NHS KAFTRIO ®

    PRESS RELEASE

    EMA recommends eight new medicines, refuses one

    RAPS

    CHMP Grants Positive Opinion for KAFTRIO® (ivacaftor/tezacaftor/elexacaftor)

    BUSINESSWIRE

    EU expands reach of Vertex` CF drug Kalydeco

    PHARMATIMES

    Vertex Receives European CHMP Positive Opinion for KALYDECO® (ivacaftor)

    BUSINESSWIRE

    Vertex Announces Innovative Reimbursement Agreement in Switzerland for ORKAMBI®

    BUSINESSWIRE

    FDA Approves 5 New Costly Drugs Well Ahead of PDUFA Dates

    RAPS

    Vertex deal with Wales expands cystic fibrosis treatment coverage to all of UK

    REUTERS

    Vertex`s cystic fibrosis portfolio to be made available across Northern

    PHARMAFILE

    ‘Impressive’ results for Trikafta in cystic fibrosis

    PHARMATIMES

    Vertex is `humming` with triple combo launch Trikafta underway: analyst

    FIERCE PHARMA

    Vertex inks agreement with NHS England for access to all licensed CF medicines

    BUSINESSWIRE

    Spanish Government Approves National Reimbursement of ORKAMBI®

    BUSINESSWIRE

    Vertex Receives European CHMP Positive Opinion for KALYDECO®

    BUSINESSWIRE

    Labour Party takes aim at pharma, calls attention to Orkambi row

    PMLIVE

    U.K.Labour Party wants government to build its own manufacturing

    FIERCE PHARMA

    Vertex deal for Scotland — no deal for England

    ENDPTS

    Vertex sinks on reports of deaths of patients taking cystic fibrosis drug

    STATNEWS

    Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.